ONCAlert | Upfront Therapy for mRCC

Breast Cancer VIEW MORE >>

Patients with early-stage breast cancer who received pelareorep demonstrated consistent data with safety run-in data and had a favorable toxicity profile, according to an cohort analysis from the window-of-opportunity study, AWARE-1.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2020 Intellisphere, LLC. All Rights Reserved.